Background: Widespread use of prostate specific antigen (PSA) in screening procedures allowed early identification of an increasing number of prostate cancers (PCas), mainly including indolent cancer. Availability of different therapeutic strategies which have a very different impact on the patient’s quality of life suggested a strong need for tools able to identify clinically significant cancer at diagnosis. Multi-parametric magnetic resonance showed very good performance in pre-biopsy diagnosis. However, it is an expensive tool and requires an experienced radiologist. In this context, a simple blood-based test is worth investigating. In this context, researchers focused their attention on the development of a laboratory test able to minimize overdiagnosis without losing the identification of aggressive tumors. Results: Recent literature data on PCa biomarkers revealed a clear tendency towards the use of panels of biomarkers or a combination of biomarkers and clinical variables. Phi, the 4Kscore, and Stockholm3 as circulating biomarkers and the Mi-prostate score, Exo DX Prostate, and Select MD-X as urinary biomarker-based tests have been developed. In this scenario, phi is worthy of attention as a noninvasive test significantly associated with aggressive PCa. Conclusions: Literature data showed that phi had good diagnostic performance to identify clinically significant (cs) PCa, suggesting that it could be a useful tool for personalized treatment decision‐making. In this review, phi potentialities, limitations, and comparisons with other blood-and urinary-based tests were explored.

Beyond PSA : The role of prostate health index (phi) / M. Ferro, O. De Cobelli, G. Lucarelli, A. Porreca, G.M. Busetto, F. Cantiello, R. Damiano, R. Autorino, G. Musi, M.D. Vartolomei, M. Muto, D. Terracciano. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1661-6596. - 21:4(2020), pp. 1184.1-1184.14. [10.3390/ijms21041184]

Beyond PSA : The role of prostate health index (phi)

O. De Cobelli;G. Musi;M. Muto;
2020

Abstract

Background: Widespread use of prostate specific antigen (PSA) in screening procedures allowed early identification of an increasing number of prostate cancers (PCas), mainly including indolent cancer. Availability of different therapeutic strategies which have a very different impact on the patient’s quality of life suggested a strong need for tools able to identify clinically significant cancer at diagnosis. Multi-parametric magnetic resonance showed very good performance in pre-biopsy diagnosis. However, it is an expensive tool and requires an experienced radiologist. In this context, a simple blood-based test is worth investigating. In this context, researchers focused their attention on the development of a laboratory test able to minimize overdiagnosis without losing the identification of aggressive tumors. Results: Recent literature data on PCa biomarkers revealed a clear tendency towards the use of panels of biomarkers or a combination of biomarkers and clinical variables. Phi, the 4Kscore, and Stockholm3 as circulating biomarkers and the Mi-prostate score, Exo DX Prostate, and Select MD-X as urinary biomarker-based tests have been developed. In this scenario, phi is worthy of attention as a noninvasive test significantly associated with aggressive PCa. Conclusions: Literature data showed that phi had good diagnostic performance to identify clinically significant (cs) PCa, suggesting that it could be a useful tool for personalized treatment decision‐making. In this review, phi potentialities, limitations, and comparisons with other blood-and urinary-based tests were explored.
Clinical significance; Overdiagnosis; Phi; Prostate cancer; Animals; Biomarkers, Tumor; Biopsy; Humans; Kallikreins; Magnetic Resonance Imaging; Male; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment
Settore MED/24 - Urologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
Beyond PSA.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 270.88 kB
Formato Adobe PDF
270.88 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/822085
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 32
social impact